These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22456294)

  • 21. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
    Forst T; Bramlage P
    Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3799-806. PubMed ID: 22855332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
    Landersdorfer CB; He YL; Jusko WJ
    Br J Clin Pharmacol; 2012 Mar; 73(3):373-90. PubMed ID: 22442825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
    Hu P; Yin Q; Deckert F; Jiang J; Liu D; Kjems L; Dole WP; He YL
    J Clin Pharmacol; 2009 Jan; 49(1):39-49. PubMed ID: 18832295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
    Ahrén B; Foley JE; Bosi E
    Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
    J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vildagliptin in the treatment of type 2 diabetes mellitus.
    Stamataros G; Schneider SH
    Expert Opin Pharmacother; 2011 Aug; 12(12):1967-73. PubMed ID: 21679097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
    Nauck MA; Kind J; Köthe LD; Holst JJ; Deacon CF; Broschag M; He YL; Kjems L; Foley J
    Diabetes; 2016 Aug; 65(8):2440-7. PubMed ID: 27207543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
    Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Deacon CF; Foley JE; Rizza RA; Camilleri M
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):737-44. PubMed ID: 18331607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
    Takayanagi R; Uchida T; Kimura K; Yamada Y
    Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vildagliptin with metformin once-daily regimen-insights from a single-center analysis.
    Chatterjee S; Chatterjee S
    Am J Ther; 2015; 22(3):195-8. PubMed ID: 23665884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
    Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
    Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.